Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials. - Wikidata - awgldk - TriplyDB

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

http://www.wikidata.org/entity/Q37841138

about

Stochastic Approximation and Modern Model-based Designs for Dose-Finding Clinical Trials.Adaptive designs for dual-agent phase I dose-escalation studies.Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.Implementing the EffTox dose-finding design in the Matchpoint trial.Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges.Evolution of early phase clinical trials in oncology.A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis.

P2860

Q37825427-E1A921F0-DFDA-4718-83DD-1384E9051142 Q38090897-AAF7E3CD-C45C-494F-BD2E-641BF658D3A2 Q38428895-0CD64A85-9C64-4A2D-B814-92DFE09F0757 Q38654251-CE8519FE-5B77-4CD6-941B-08F381653BD8 Q38697445-BBEE3933-A697-4A08-BBF5-4AD68E57F814 Q47816379-D32DF4B3-102B-4423-BC82-1E920F2A76FE Q51317650-8567DE53-28AA-4FE6-AEE4-33354534DF40

P2860

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

http://www.wikidata.org/entity/Q37841138

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

@en

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

@nl

type

label

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

@en

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

@nl

prefLabel

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

@en

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

@nl

P1433

Q37841138-AB2D64EB-6A14-48D5-8275-9C840213D14D

P1476

Q37841138-3388F719-F255-4ECA-98D8-47042A17D2F4

P2093

Q37841138-095CCFF9-1E81-47E0-9D4B-D3E85275EC55

P2860

Q37841138-03A9CEDC-BC48-4AAB-B5A7-8A89DCA37B97

Q37841138-1BF6D6A9-FDC8-48AA-B857-BDC57CF0471E

Q37841138-1F5168ED-0764-4CE8-A620-53961AE230FD

Q37841138-3AFED475-EDA0-4F36-9BF1-5E3DD25E7A09

Q37841138-5DC50D83-111D-4891-A43D-99462FA51F16

Q37841138-5E67126A-BB8A-4B10-99E4-4E6CF37E6CFA

Q37841138-68371B91-5D6E-4771-95A6-C2D95507016B

Q37841138-6DC76F0D-12D3-462F-8C64-097EBC31E5F3

Q37841138-85BA060A-0670-43A5-B23C-F037B849F2D6

Q37841138-894E2EC6-C38C-4F40-A501-9C476E7DE0CC

P304

Q37841138-B0794B8B-191A-4553-A86E-242CE09E063A

P31

Q37841138-DCCF7A8F-D107-4B7D-B7A1-34AD75FE86A2

P356

Q37841138-03403536-DEFB-45AC-B891-9ED9CAB32993

P407

Q37841138-053427D2-F9BE-4EDA-B187-123679551268

P433

Q37841138-4F873C29-C7E7-4A2C-8669-D41E694A71A3

P478

Q37841138-BC9D6A44-8C17-41B0-9593-31695F660B8E

P577

Q37841138-FB7BA636-511B-4A8C-B6F4-EFC7CF5FE4E2

P698

Q37841138-5CECEB9A-CECC-4EAC-A3A5-C9022494029A

P818

Q37841138-122F591B-BE21-404B-A94E-5C9DA5F58EFB

P932

Q37841138-141324B8-0147-44F2-B710-41C9B3F53128

P356

P1433

Statistical Science

P1476

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

@en

P2093

Peter F Thall

http://www.w3.org/2001/XMLSchema#string

P2860

Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-as-we-go?

Monitoring late-onset toxicities in phase I trials using predicted risks

Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.

Sequential design and analysis of dose finding studies in patients with life threatening disease.

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

Determining the effective sample size of a parametric prior

Parametric non-mixture cure models for schedule finding of therapeutic agents.

The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes.

Dose-finding with two agents in Phase I oncology trials.

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

P304

227-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1214/09-STS315

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21318084

http://www.w3.org/2001/XMLSchema#string

P818

1011.6494

http://www.w3.org/2001/XMLSchema#string

P932

3035990

http://www.w3.org/2001/XMLSchema#string